Wedbush Predicts Weaker Earnings for Mersana Therapeutics
Wedbush decreased their Q1 2025 earnings estimates for Mersana Therapeutics in a report issued on Monday, March 3rd. Wedbush ...
Mersana Therapeutics reports Q4 EPS (11c), consensus (17c)
Reports Q4 revenue $16.361M, consensus $7.71M. “We made significant progress advancing the clinical development of Emi-Le in 2024,” said Martin ...
The Manila Times11d
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results
Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-Le Initiated first ...
Mersana Therapeutics’ (MRSN) “Outperform” Rating Reaffirmed at Wedbush
Wedbush reaffirmed their outperform rating on shares of Mersana Therapeutics (NASDAQ:MRSN – Free Report) in a research report ...
Nasdaq11d
Mersana Therapeutics Reports Positive Initial Phase 1 Data for Emi-Le and Receives Additional Fast Track Designation
Mersana Therapeutics announced promising Phase 1 results for Emi-Le in TNBC and received Fast Track designation from the FDA. Mersana Therapeutics, Inc. announced positive initial Phase 1 clinical ...
Investing3d
Mersana at Leerink Global Healthcare Conference: Strategic ADC Insights
On Tuesday, 11 March 2025, Mersana Therapeutics (NASDAQ: MRSN) took center stage at the Leerink Global Healthcare Conference 2025. The company showcased its innovative Antibody-Drug Conjugate (ADC ...
William Blair Sticks to Their Hold Rating for Nektar Therapeutics (NKTR)
William Blair analyst Andy Hsieh reiterated a Hold rating on Nektar Therapeutics (NKTR – Research Report) today. The company’s shares closed ...
Nasdaq11d
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.16 per share a year ago.